ARS Pharmaceuticals (SPRY) reported a Q1 net loss Wednesday of $0.35 per diluted share, wider than a loss of $0.11 a year earlier.
Analysts polled by FactSet expected a loss of $0.32.
Revenue for the quarter ended March 31 was $8 million.
Analysts surveyed by FactSet expected $7.5 million.
As of March 31, the company said it had $275.7 million in cash and cash equivalents on hand, and expected it could fund operations through the next three years.
ARS' shares were 1.1% higher in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.